Shares in Reckitt Benckiser (LON: RKT) fell around 1.7% on Monday, dropping to 5,026p from a previous close of 5,114p, as its US subsidiary Mead Johnson entered the first bellwether trial in a sprawling multidistrict litigation (MDL) over its Enfamil infant formula.
The case, being heard in US federal court, is the first of thousands of lawsuits consolidated under the necrotizing enterocolitis (NEC) baby formula MDL. Plaintiffs allege that Mead Johnson, along with rival Abbott Laboratories, failed to adequately warn parents and hospitals that cow’s-milk-based formulas such as Enfamil could raise the risk of NEC — a severe and sometimes fatal intestinal disease that predominantly affects premature infants. Reckitt and Mead Johnson deny the allegations and maintain that their products are safe when used as directed.
Bellwether trials are used in mass litigation to test how juries respond to representative claims, often shaping the settlement strategy for the remaining cases. Abbott has already faced several similar trials, including a $70 million verdict earlier this year, intensifying scrutiny on the wider industry and adding pressure on Reckitt as the litigation risk becomes more tangible for investors.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Monday’s share price weakness reflects growing investor unease over the potential financial and reputational fallout, even though Reckitt has repeatedly said it believes the claims are without merit and intends to defend itself vigorously. Analysts have flagged the Mead Johnson litigation as a key overhang on the stock, with some arguing Reckitt’s core brands remain undervalued despite the legal risk.
The outcome of this bellwether trial will be closely watched as an early signal of how US courts — and juries — may treat the thousands of similar claims still pending against the company.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Learn Stock Trading
Latest News